Pharmacokinetics and Pharmacodynamics Practice Questions

Q: Zero order kinetics is followed by all of the following drugs EXCEPT?

Barbiturates. The core concept here is the difference between **First-order** and **Zero-order kinetics**. Most drugs follow first-order kinetics, where a constant *fraction* of the drug is eliminated per unit time [1]. In contrast, zero-order kinetics occurs when the elimination processes (usually enzymes) become saturated; a constant *amount* of the drug is eliminated regardless of its plasma concentration [1]. **1. Why Barbiturates is the correct answer:** Most **Barbiturates** (like Phenobarbital) follow **First-order kinetics**. Their rate of elimination is proportional to the plasma concentration [1]. While very high doses can lead to saturation, they are classically categorized as first-order drugs in standard pharmacological teaching. **2. Analysis of Incorrect Options (Drugs following Zero-order kinetics):** * **Phenytoin (A):** It follows zero-order kinetics at therapeutic or high concentrations (Michaelis-Menten kinetics). Small dose increases can lead to disproportionately large increases in plasma levels, causing toxicity [1]. * **Alcohol/Ethanol (C):** It is the classic example of zero-order kinetics. The enzyme alcohol dehydrogenase is saturated even at low social drinking levels [1]. * **Theophylline (D):** At higher therapeutic ranges, theophylline's metabolism becomes saturated, shifting from first-order to zero-order kinetics. **3. High-Yield Clinical Pearls for NEET-PG:** To remember the drugs following Zero-order kinetics, use the mnemonic **"WATT"** or **"Zero WATTS"**: * **W** – Warfarin (at very high doses) * **A** – Alcohol / Aspirin (at high doses) * **T** – Theophylline * **T** – Tolbutamide * **S** – Salicylates / **S**-Phenytoin **Key distinction:** Zero-order kinetics is also called **"Capacity-limited elimination"** or **"Non-linear kinetics."** In these drugs, the half-life ($t_{1/2}$) is not constant; it increases as the dose increases [1].

Q: If a drug is excreted in urine at the rate of 10 mg/hr at a steady-state plasma concentration of 5 mg/L, then its renal clearance is:

2.0 L/hr. ### Explanation **Concept and Calculation:** Renal clearance ($CL_r$) is defined as the volume of plasma that is completely cleared of a drug by the kidneys per unit of time. It is calculated using the formula: $$CL_r = \frac{\text{Rate of Elimination (Urine)}}{\text{Plasma Concentration (Cp)}}$$ In this question: * **Rate of elimination** = $10\text{ mg/hr}$ * **Steady-state plasma concentration ($C_{ss}$)** = $5\text{ mg/L}$ * **Calculation:** $CL_r = \frac{10\text{ mg/hr}}{5\text{ mg/L}} = \mathbf{2.0\text{ L/hr}}$ **Analysis of Options:** * **Option B (2.0 L/hr) is Correct:** This directly follows the standard clearance formula. * **Option A (0.5 L/hr):** This is an error resulting from dividing plasma concentration by the elimination rate ($5/10$), which is mathematically incorrect. * **Option C (5.0 L/hr):** This value does not correlate with the provided data; it may be a distractor using the plasma concentration value. * **Option D (20 L/hr):** This results from multiplying the two values ($10 \times 2$) instead of dividing them. **NEET-PG High-Yield Pearls:** 1. **Clearance vs. Elimination:** Clearance is a **volume** per unit time (L/hr), whereas the elimination rate is an **amount** per unit time (mg/hr). 2. **Comparison with GFR:** * If $CL_r \text{GFR}$, the drug undergoes **active tubular secretion**. 3. **Loading Dose:** Clearance determines the **Maintenance Dose**, while Volume of Distribution ($V_d$) determines the **Loading Dose**. 4. **First-order Kinetics:** For most drugs, clearance remains constant regardless of plasma concentration.

Q: Which of the following drugs does not produce active metabolites?

Lisinopril. The core concept tested here is the difference between **active drugs** and **prodrugs**. A prodrug is pharmacologically inactive and must be metabolized (usually by the liver) into an active metabolite to exert its effect [2]. **1. Why Lisinopril is the correct answer:** Most ACE inhibitors are prodrugs (e.g., Enalapril to Enalaprilat) to improve oral bioavailability. However, **Lisinopril** and **Captopril** are the two major exceptions. Lisinopril is an active drug; it is not metabolized by the liver and is excreted unchanged in the urine. Therefore, it does not produce active metabolites [1]. **2. Analysis of Incorrect Options:** * **Enalapril (Option A):** It is a prodrug converted by hepatic esterases into its active form, **Enalaprilat** [1]. * **Prednisone (Option C):** It is a corticosteroid prodrug that must be converted in the liver by the enzyme 11β-HSD to its active form, **Prednisolone** [3]. * **Sulfasalazine (Option D):** It is broken down by colonic bacteria into **Sulfapyridine** and **5-aminosalicylic acid (5-ASA)**; the latter is the active moiety used in treating Ulcerative Colitis [4]. **High-Yield Clinical Pearls for NEET-PG:** * **ACE Inhibitor Exceptions:** Remember the mnemonic **"CL"** (Captopril and Lisinopril) as the ACE inhibitors that are *not* prodrugs. * **Lisinopril** is preferred in patients with liver disease because it does not require hepatic activation. * **Active Drugs vs. Prodrugs:** Most drugs are active as administered. Common prodrugs to remember for exams include Levodopa (to Dopamine), Cyclophosphamide (to Phosphoramide mustard), and Clopidogrel.

Q: Excretion of barbiturates in the urine can be increased by which of the following interventions?

Urinary alkalinization. **Explanation:**The excretion of barbiturates (specifically Phenobarbital) is increased by **urinary alkalinization** through the principle of **ion trapping**.**1. Why Urinary Alkalinization is Correct:**Barbiturates are **weakly acidic** drugs. According to the Henderson-Hasselbalch principle, acidic drugs remain non-ionized in acidic environments and become **ionized (charged)** in alkaline environments. By administering Sodium Bicarbonate ($NaHCO_3$) to alkalinize the urine, the barbiturate molecules become ionized. Since ionized drugs are lipid-insoluble, they cannot be reabsorbed across the renal tubular epithelium back into the blood and are instead "trapped" in the tubular lumen and excreted [1].**2. Why Other Options are Incorrect:** * **Diuretics (A):** While forced diuresis increases urine volume, it is significantly less effective than altering pH for weak acids and is no longer the primary recommendation due to the risk of pulmonary edema. * **Urinary Acidification (C):** This would keep the acidic barbiturate in a non-ionized, lipid-soluble state, promoting its reabsorption into the systemic circulation and worsening toxicity. (Acidification is used for weak bases like Amphetamines). * **Hemodialysis (D):** While effective for severe poisoning, it is an invasive procedure. Urinary alkalinization is the first-line pharmacological intervention for enhancing renal clearance.**Clinical Pearls for NEET-PG:** * **Mnemonic:** **A**cidic drugs are excreted in **A**lkaline urine (e.g., Barbiturates, Salicylates, Methotrexate). * **Agent used:** Intravenous **Sodium Bicarbonate** is the drug of choice for urinary alkalinization. * **Target pH:** The goal is to maintain a urinary pH between **7.5 and 8.5**. * **Note:** Only long-acting barbiturates like **Phenobarbital** are significantly excreted by the kidneys; short-acting ones are primarily metabolized by the liver.

Q: ED50 is used for determining which of the following?

Potency. **Explanation:** **1. Why Potency is Correct:** Potency refers to the amount of drug (dose) required to produce an effect of a given intensity. It is measured by the **ED50 (Median Effective Dose)**, which is the dose required to produce a specified therapeutic effect in 50% of the population (in quantal dose-response curves) or the dose that produces 50% of the maximal response (in graded curves). A drug with a lower ED50 is considered more potent because a smaller dose is needed to achieve the same effect. **2. Why Other Options are Incorrect:** * **B. Efficacy:** This refers to the maximum effect ($E_{max}$) a drug can produce, regardless of dose. It is determined by the height of the dose-response curve, not the ED50. * **C. Safety:** Safety is determined by the **Therapeutic Index (TI)**, which is the ratio of the median lethal dose to the median effective dose ($TI = LD_{50} / ED_{50}$). * **D. Toxicity:** This is measured by the **TD50 (Median Toxic Dose)**, which is the dose that produces a specific toxic effect in 50% of the population. **Clinical Pearls for NEET-PG:** * **Potency vs. Efficacy:** Efficacy is clinically more important than potency. For example, Furosemide is more efficacious than Thiazides (it can remove more fluid), even if a Thiazide might be more potent (requiring fewer milligrams). * **Drug Comparison:** On a dose-response graph, if Curve A is to the **left** of Curve B, Drug A is more **potent**. If Curve A is **higher** than Curve B, Drug A has higher **efficacy**. * **Therapeutic Window:** The range between the minimum effective therapeutic concentration and the minimum toxic concentration.

Q: Which of the following is an example of learned tolerance?

Walking a straight line when intoxicated. **Explanation:** **Learned Tolerance** (also known as behavioral tolerance) refers to a reduction in the effects of a drug that results from compensatory mechanisms learned by the individual through experience. It occurs when a person performs a task repeatedly while under the influence of a drug, eventually learning to function effectively despite the impairment. **Why Option C is Correct:** Walking a straight line while intoxicated is the classic example of learned tolerance. An individual who frequently consumes alcohol learns to consciously coordinate their motor movements and utilize visual cues to compensate for the cerebellar ataxia and vestibular impairment caused by ethanol. This is a behavioral adaptation rather than a change in drug metabolism or receptor sensitivity. **Analysis of Incorrect Options:** * **Options A, B, and D** represent **behavioral modifications** or safety strategies. Avoiding alcohol when unsteady, eating food to slow absorption (pharmacokinetic intervention), or choosing not to drive are conscious decisions to mitigate risk, but they do not involve the physiological or psychological "learning" to overcome a drug-induced deficit while the drug is active in the system. **High-Yield NEET-PG Pearls:** 1. **Pharmacodynamic Tolerance:** Occurs due to adaptive changes in the biological system (e.g., down-regulation of receptors like GABA receptors in chronic benzodiazepine use). 2. **Pharmacokinetic (Metabolic) Tolerance:** Occurs when the drug induces its own metabolism (e.g., Carbamazepine or Phenobarbitone inducing Cytochrome P450 enzymes). 3. **Tachyphylaxis:** A form of acute tolerance where drug effects diminish rapidly after only a few doses (e.g., Ephedrine, Tyramine, Nitroglycerin). 4. **Reverse Tolerance (Sensitization):** An increase in response to the same dose of a drug with repeated use (e.g., Cocaine-induced seizures).

Q: Which of the following statements regarding plasma protein binding is NOT true?

Nephrotic syndrome does not affect plasma protein binding.. ### Explanation **1. Why Option C is the Correct Answer (The "NOT True" Statement):** Plasma protein binding is significantly altered in **Nephrotic Syndrome**. This condition is characterized by massive proteinuria, leading to **hypoalbuminemia**. Since many drugs (especially acidic ones) rely on albumin for transport, a decrease in albumin levels results in a higher **free fraction** of the drug. This can lead to increased pharmacological effects or potential toxicity even at standard doses. Therefore, saying it "does not affect" binding is medically incorrect. **2. Analysis of Incorrect Options:** * **Option A:** This is a fundamental principle. Only the **free (unbound) fraction** can cross biological membranes, interact with receptors, and undergo metabolism/excretion. The bound fraction acts as a reservoir. * **Option B:** Generally, **acidic drugs** (e.g., NSAIDs, Warfarin, Phenytoin) bind to **Albumin**, while **basic drugs** (e.g., Lidocaine, Propranolol) bind to **Alpha-1-acid glycoprotein (AAG)**. * **Option D:** Prazosin is a basic drug. Basic drugs predominantly bind to **Alpha-1-acid glycoprotein**, making this statement true. **3. High-Yield Clinical Pearls for NEET-PG:** * **Albumin vs. AAG:** Albumin levels decrease in liver disease and nephrotic syndrome. AAG is an "acute-phase reactant"; its levels **increase** during inflammation, surgery, or myocardial infarction, potentially decreasing the free fraction of basic drugs. * **Displacement Interactions:** Highly protein-bound drugs (e.g., Warfarin) can be displaced by other drugs (e.g., Sulfonamides), leading to a sudden spike in the free fraction and toxicity. * **Volume of Distribution (Vd):** Drugs with high plasma protein binding typically have a **low Vd**, as they are sequestered within the vascular compartment.

Question 1

A pharmacology researcher is studying the interaction of a new drug with a receptor system. Two candidate antagonist compounds (Drug X and Drug Y) are tested against a standard agonist at increasing concentrations. The resulting dose-response curves are plotted (Image 1). In the graph, the X-axis represents Log [Agonist Concentration (mol/L)] and the Y-axis represents % Maximum Response (0–100%). Three labeled sigmoid curves are shown: (1) 'Control' — the agonist alone, reaching 100% Emax; (2) 'Drug X + Agonist' — a parallel rightward shift of the control curve with unchanged Emax (~100%); (3) 'Drug Y + Agonist' — a rightward shift with a clearly depressed/lowered Emax (~50–60%). Based on the curves, which of the following statements best describes the mechanism of Drug Y?

Accepted Answer

B. Drug Y binds irreversibly or allosterically to reduce the maximal efficacy of the agonist, and its effect cannot be surmounted by increasing agonist concentration

Answer

A. Drug Y competes reversibly with the agonist at the orthosteric binding site, and its effect can be overcome by increasing agonist concentration

Answer

C. Drug Y acts as a partial agonist, producing a submaximal response that blunts the full agonist curve without shifting the EC50

Answer

D. Drug Y increases the affinity of the agonist for the receptor, producing a leftward shift in the dose-response curve with an elevated Emax

Question 2

Zero order kinetics is followed by all of the following drugs EXCEPT?

Accepted Answer

Barbiturates

Answer

Phenytoin

Answer

Alcohol

Answer

Theophylline

Question 3

If a drug is excreted in urine at the rate of 10 mg/hr at a steady-state plasma concentration of 5 mg/L, then its renal clearance is:

Accepted Answer

2.0 L/hr

Answer

0.5 L/hr

Answer

5.0 L/hr

Answer

20 L/hr

Question 4

A drug with a plasma half-life of 12 hours is administered twice a day. Steady-state plasma concentration reached is 300 mg/dl. Which of the following statements about this drug is not true?

Accepted Answer

Intravenous administration will always achieve a higher concentration than the oral route.

Answer

Plasma concentration will be approximately 260 mg/dl after three half-lives of initiation of therapy.

Answer

After changing the dose, plasma concentration should be measured after 3 days.

Answer

Doubling the dose will double the plasma concentration after 3 days.

Question 5

Which of the following drugs does not produce active metabolites?

Accepted Answer

Lisinopril

Answer

Enalapril

Answer

Prednisone

Answer

Sulfasalazine

Question 6

Excretion of barbiturates in the urine can be increased by which of the following interventions?

Accepted Answer

Urinary alkalinization

Answer

Diuretics

Answer

Urinary acidification

Answer

Hemodialysis

Question 7

ED50 is used for determining which of the following?

Accepted Answer

Potency

Answer

Efficacy

Answer

Safety

Answer

Toxicity

Question 8

Which of the following is an example of learned tolerance?

Accepted Answer

Walking a straight line when intoxicated

Answer

Avoiding alcohol when feeling unsteady

Answer

Drinking alcohol only with food

Answer

Not driving when drunk

Question 9

Sodium thiopental is ultra-short acting due to –

Accepted Answer

Rapid redistribution

Answer

Rapid absorption

Answer

Rapid metabolism

Answer

Rapid excretion

Question 10

Which of the following statements regarding plasma protein binding is NOT true?

Accepted Answer

Nephrotic syndrome does not affect plasma protein binding.

Answer

The free fraction of a drug is considered pharmacologically active.

Answer

Acidic drugs typically bind to plasma albumin.

Answer

Prazosin is bound to alpha-1-acid glycoprotein.

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?